CVS HEALTH CORPORATION
CVS
$73.49
+1.38%
CVS Health Corporation is a diversified healthcare services company operating in the Medical - Healthcare Plans industry. It is a vertically integrated healthcare giant, combining retail pharmacy, pharmacy benefit management (PBM), and health insurance operations under one roof.
CVS
CVS HEALTH CORPORATION
$73.49
Investment Opinion: Should I buy CVS Today?
Based on a synthesis of the data, the objective assessment is a Hold. The stock's deeply discounted valuation on sales and forward earnings is compelling for value-oriented investors, and the strong free cash flow provides a margin of safety. However, the extreme earnings volatility, weak profitability metrics, and clear negative technical momentum advise against initiating a new position until there is concrete evidence of earnings stabilization and a reversal in price trend. The mixed analyst actions (Buys, Outperforms, and Market Performs) reflect this uncertainty.
Sign up to view all
CVS 12-Month Price Forecast
The data presents a conflicted picture: compelling valuation vs. alarming operational instability. The neutral stance reflects high uncertainty; the stock is not cheap enough to ignore the fundamental flaws, nor are the flaws severe enough to dismiss the valuation support entirely. The path depends almost entirely on earnings consistency.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CVS HEALTH CORPORATION's 12-month outlook, with a consensus price target around $95.54 and implied upside of +30.0% versus the current price.
Average Target
$95.54
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$59 - $96
Analyst target range
Data not available. The provided analyst data includes revenue and EPS estimates but lacks consensus target price and ratings distribution information. Recent institutional rating actions show a mix of 'Buy', 'Outperform', and 'Market Perform' recommendations from various firms, but a quantitative summary of analyst consensus is not available from the inputs.
Bulls vs Bears: CVS Investment Factors
CVS presents a classic value trap scenario: superficially cheap on sales and forward earnings, but plagued by severe profitability issues and high leverage. The vertically integrated model is a long-term strength, but recent quarterly volatility and poor stock performance underscore significant operational and market sentiment challenges. The investment thesis hinges on whether management can stabilize earnings.
Bullish
- Attractive Valuation Multiples: Forward P/E of 8.79 and P/S of 0.25 suggest the stock is inexpensive.
- Strong Free Cash Flow: TTM FCF of $7.8B provides financial flexibility for dividends and buybacks.
- Resilient Revenue Growth: Q4 2025 revenue grew 8.17% YoY, showing core business strength.
- Vertical Integration Synergies: Combined retail, PBM, and insurance creates a unique, defensible model.
Bearish
- Extreme Profit Volatility: Massive Q3 loss followed by Q4 profit indicates unstable earnings.
- Poor Profitability Metrics: Trailing net margin of 0.44% and low ROE/ROA signal inefficiency.
- High Financial Leverage: Debt-to-equity of 1.24 increases risk during economic downturns.
- Severe Technical Weakness: Stock down ~10% in 1M & 3M, significantly underperforming the S&P 500.
CVS Technical Analysis
The stock has exhibited a volatile and overall declining trend over the last six months, with the price falling from around $77.45 in early October 2025 to $71.82 by the end of March 2026. The 1-month and 3-month price changes are -10.11% and -9.50% respectively, significantly underperforming the broader market as indicated by negative relative strength figures of -4.86 and -4.87 against the S&P 500. The stock's current price of $71.82 is near the lower end of its 52-week range of $58.35 to $85.15, trading approximately 15.7% below the 52-week high. No RSI data was provided for further momentum analysis.
Beta
0.46
0.46x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$58-$85
Price range past year
Annual Return
+8.0%
Cumulative gain past year
| Period | CVS Return | S&P 500 |
|---|---|---|
| 1m | -8.7% | -3.6% |
| 3m | -8.3% | -4.0% |
| 6m | -5.2% | -2.0% |
| 1y | +8.0% | +16.2% |
| ytd | -8.3% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVS Fundamental Analysis
Revenue growth has been positive, with Q4 2025 revenue of $105.7 billion representing an 8.17% year-over-year increase. However, profitability has been inconsistent; while Q4 2025 showed a net income of $2.94 billion, the preceding Q3 2025 reported a significant net loss of -$3.98 billion, leading to a very low trailing twelve-month net margin of 0.44%. Financial health shows a debt-to-equity ratio of 1.24, indicating a leveraged balance sheet, but the company maintains a strong trailing free cash flow of $7.8 billion. Operational efficiency metrics are mixed, with a low Return on Equity (ROE) of 2.35% and a low Return on Assets (ROA) of 2.47%, suggesting challenges in generating profits from its asset base.
Quarterly Revenue
$105.7B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.12%
Latest Quarter
Free Cash Flow
$7.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVS Overvalued?
Given the company's positive net income in the latest quarter, the primary valuation metric is the P/E ratio. The trailing P/E ratio is elevated at 56.87, largely due to the low trailing EPS of $0.018. The forward P/E ratio is a more reasonable 8.79, based on analyst EPS estimates. The stock also trades at a low Price-to-Sales (P/S) ratio of 0.25 and an EV-to-Sales of 0.40, which appear inexpensive relative to its revenue base. Peer comparison data for industry averages was not provided in the valuation inputs.
PE
56.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -9x~227x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.8x
Enterprise Value Multiple
Investment Risk Disclosure
CVS faces substantial operational, financial, and market risks. Operationally, the extreme volatility in quarterly net income (from a $4B loss in Q3 to a $2.9B profit in Q4) indicates potential one-time charges, integration issues from acquisitions, or pricing pressures in its PBM/insurance segments. This makes future earnings highly unpredictable. Financially, the company carries significant leverage with a debt-to-equity ratio of 1.24, which could strain cash flow if interest rates remain elevated or if earnings deteriorate further. The low current ratio of 0.84 also points to potential short-term liquidity constraints.
Market risks are pronounced, as evidenced by the stock's severe underperformance. A -10.11% 1-month return against a -5.25% move for the S&P 500 shows deep negative sentiment. The stock is trading near the lower end of its 52-week range, and the high short interest ratio of 2.36 suggests a sizable portion of the market is betting on further declines. Regulatory risks are ever-present for a large healthcare conglomerate, impacting drug pricing, insurance reimbursements, and pharmacy operations.
FAQ
The primary risks are operational instability and financial leverage. The huge swing from a Q3 2025 net loss to a Q4 profit shows earnings are unpredictable, potentially due to acquisition integration or pricing pressures. Financially, the debt-to-equity ratio of 1.24 is elevated. Market risk is also high, with the stock showing severe negative momentum, underperforming the S&P 500 by ~5% over the last three months.
The 12-month outlook is range-bound with a neutral bias. The base case (55% probability) sees the stock trading between $70 and $85, supported by its low valuation but capped by profitability concerns. A bull case to $95 is possible if earnings stabilize, while a bear case could retest the 52-week low of $58.35 if volatility persists. The forward P/E of 8.79, based on analyst EPS estimates of ~$11.47, provides a fundamental anchor.
CVS sends mixed valuation signals. It appears deeply undervalued on a forward earnings basis (P/E of 8.79) and on sales (P/S of 0.25). However, the trailing P/E of 56.87 is extremely high due to depressed trailing EPS. The low price-to-sales multiple is the clearest sign of undervaluation, but this is offset by concerns over the company's ability to convert those sales into stable, high-quality profits.
CVS is a speculative buy at current levels. It trades at a very reasonable forward P/E of 8.79 and a low P/S ratio of 0.25, which is attractive. However, its extreme quarterly earnings volatility, including a massive $4 billion loss in Q3 2025, makes it a high-risk proposition. It is more suitable for risk-tolerant investors seeking deep value, rather than a core holding.
CVS is only suitable for a long-term investment horizon, and only for investors with high risk tolerance. The short-term outlook is clouded by extreme earnings volatility and negative price momentum. A long-term view allows time for the company's vertical integration strategy to potentially deliver more stable profits and for the current low valuation multiples to normalize. It is not a trading stock for short-term gains.